Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ganetespib (ADX-1612)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Aldeyra

Drug class:

HSP90 inhibitor

Related drugs:

TP53 mutation	Ovarian Cancer	TP53 mutation	Ovarian Cancer	ADX-1612 Sensitive: C2 – Inclusion Criteria ADX-1612 Sensitive : C2	ADX-1612 Sensitive: C2 – Inclusion Criteria ADX-1612 Sensitive : C2
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	ADX-1612 Sensitive: D – Preclinical ADX-1612 Sensitive : D	ADX-1612 Sensitive: D – Preclinical ADX-1612 Sensitive : D
BCR-FGFR1 fusion	Leukemia	BCR-FGFR1 fusion	Leukemia	ADX-1612 Sensitive: D – Preclinical ADX-1612 Sensitive : D	ADX-1612 Sensitive: D – Preclinical ADX-1612 Sensitive : D
BCR-FGFR1 fusion	Leukemia	BCR-FGFR1 fusion	Leukemia	infigratinib + ADX-1612 Sensitive: D – Preclinical infigratinib + ADX-1612 Sensitive : D	infigratinib + ADX-1612 Sensitive: D – Preclinical infigratinib + ADX-1612 Sensitive : D
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	ADX-1612 Sensitive: D – Preclinical ADX-1612 Sensitive : D	ADX-1612 Sensitive: D – Preclinical ADX-1612 Sensitive : D
EML4-ALK fusion	Non Small Cell Lung Cancer	EML4-ALK fusion	Non Small Cell Lung Cancer	ADX-1612 Sensitive: D – Preclinical ADX-1612 Sensitive : D	ADX-1612 Sensitive: D – Preclinical ADX-1612 Sensitive : D